Indorama Ventures Public Company Limited for the year ended December 31, 2019 We are pleased to submit: 1. Consolidated and Company only Annual Audited Financial Statements for the year ended December 31

-2021 6M-2020 6M-2021 Change THB Mn THB Mn THB Mn %QoQ %YoY THB Mn THB Mn %YoY Sales of goods and services 1,139.5 1,214.9 1,284.4 5.7% 12.7% 2,255.2 2,499.3 10.8% Revenue from finance lease under power

of receivable under finance lease agreement, gain on forward contracts and insurance claim. Change Consolidated financial statements Financial Performance of the Group 2 Sales and service income for

(“the Group”) as follow: Consolidated financial statements Q3-2021 Q2-2022 Q3-2022 9M-2021 9M-2022 THB Mn THB Mn THB Mn %QoQ %YoY THB Mn THB Mn %YoY Sales of goods and services 1,362.8 1,542.4 1,705.4

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

per visit increased to over THB 1,600. Despite the slight Operation : Consolidated Profit & Loss Statement 1Q 1Q % Unit : THB million 2019 2018 change Revenue from non-social security 248.35 218.24 14

) (32,536) -10% Impairment of investment in subsidiary - - (3,723) - 100% Finance costs (28,569) (33,716) -15% (13,738) (19,474) -29% 4 THB’000 Consolidated ∆% Separate ∆% 1Q2019 1Q2018 1Q2019 1Q2018 Profit

2019, the Company had earnings before interest, tax, depreciation and amortization( EBITDA) from operation pursuant Consolidated Financial Statements in the amount of THB 94.17 million decreased by THB

2019, the Company had earnings before interest, tax, depreciation and amortization (EBITDA) from operation and pursuant Consolidated Financial Statements in the amount of THB 239. 61 million decreased by

earnings before interest, tax, depreciation and amortization (EBITDA) from operation pursuant Consolidated Financial Statements in the amount of THB 81 million decreased by THB 13 million or 14.1 percent